Pharmaceutical composition for the treatment of acute disorders

Abstract

A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.

1 - 18 . (canceled) 
     
     
         19 : A method for treating an acute disorder selected from the group consisting of pain, insomnia, an allergic condition, hypercoagulation, hypertension, diabetes and pulmonary oedema, comprising administering sublingually, to an individual afflicted with said disorder at least one dose unit of a composition comprising
 an effective amount of at least one pharmaceutically active agent in the form of microparticles adhered to the surfaces of water-soluble carrier particles which are substantially larger than said microparticles;   a bioadhesion; and   optionally a mucoadhesion promoting agent,   
       wherein the carrier particles each have a mean sieve diameter of 50 to 750 um. 
     
     
         20 : The method according to  claim 19 , wherein the pharmaceutically active agent is selected from the group consisting of morphine, alfentanyl, sufentanyl, buprenorphine, pizotifen, sumatritptan, indomethacin, sulindac, dielofenac, ketorolac, piroxicam, tenoxicam, ibuprofen, naproxen, ketoprofen, butazolidine, phenylbutazone, diazepam, oxazepam, zoipielone, zolpidem, propriomazin, valeriana, levomepromazin, a sleep-inducing peptide, cyclizine, cetirizine, terfenadine, acrivastine and fexofenadine or a pharmaceutically acceptable salt thereof. 
     
     
         21 . (canceled) 
     
     
         22 : The method according to claim  1 - 9 , wherein the disorder is pain and the pharmaceutically active agent is alfentanyl or sufentanyl. 
     
     
         23 : The method according to  claim 19 , wherein the disorder is insomnia and the pharmaceutically active agent is zolpidem. 
     
     
         24 : The method according to  claim 19 , further comprising administering a diuretic acid and the pharmaceutically active agent is selected from the group consisting of furosemide, an atrial natriuretic peptide and a brain natriuretic peptide. 
     
     
         25 : The method according to  claim 19 , wherein the disorder is hypercoagulation and the pharmaceutically active agent is selected from the group consisting of a platelet aggregation inhibitor, strepokinase, heparin and urokinase. 
     
     
         26 : The method according to  claim 19 , wherein the disorder is hypertension and the pharmaceutically active agent is a renin inhibitor. 
     
     
         27 : The method according to  claim 19 , wherein the disorder is hypercoagulation and the pharmaceutically active agent is selected from the group consisting of a platelet aggregation inhibitor, strepokinase, heparin and urokinase. 
     
     
         28 : The method according to  claim 19 , wherein the disorder is diabetes and the pharmaceutically active agent is insulin. 
     
     
         29 : The method according to  claim 19 , further comprising reducing gastric acid production in the individual by administering a pharmaceutically active agent selected from the group consisting of a H + -ATPase inhibitor and a K + -ATPase inhibitor 
     
     
         30 : The method according to  claim 29 , wherein the pharmaceutically active agent selected from the group consisting of omeprazole, pantoprazole, perprazole, lansoprazole, allyl isothiocyanante, trifluoroperazide, nolinium bromide, RP 40749 and fenoctimine.